Scientists crack chemical code of incredibly complex 'anti-tumor antibiotic'

After 20 years of dedicated research, scientists have cracked the chemical code of an incredibly complex 'anti-tumor antibiotic' known to be highly effective against cancer cells as well as drug-resistant bacteria, and have reproduced it synthetically in the lab for the first time.

This major breakthrough and world-first could hail a new era in the design and production of new antibiotics and anticancer agents.

The 'super substance' - kedarcidin - was discovered in its natural form by a pharmaceutical company when they extracted it from a soil sample in India almost 30-years-ago. Soil is the natural source of all antibiotics developed since the 1940s but in order for them to be developed as potential drug treatments they must be produced via chemical synthesis.

Unlike many other antibiotics which focus solely on killing bacteria, kedarcidin is also capable of harming tumor cells and has potential as an effective cancer treatment.

Kedarcidin is incredible in its biological activity, as it works by causing DNA damage to its target, but also in its structural complexity. It has been the subject of extensive research by scientists around the world but because of its complex structure they have been unable to reproduce it in its most complete and accurate form, until now.

Dr Martin Lear at the University of Lincoln, UK, and Professor Masahiro Hirama, based at Tohoku University in Japan, have become the first scientists in the world to create a total synthesis of this highly unstable natural product. Their findings are published in The Journal of Antibiotics from Nature.

Dr Martin Lear, Reader in the School of Chemistry at the University of Lincoln, explained: "Following its discovery in soil it took 10 years to determine the molecular structure of kedarcidin. With a reactive core protected by a protein cloak, it resembles something like a scotch egg!

"In 1997, I began the long journey of making kedarcidin's reactive core with Professor Hirama, who was recently awarded the highest honor for a scientist in Japan. We basically needed to piece together a molecular puzzle of remarkable difficulty and then develop new ways of making the jigsaw pieces. 20 years later we have finally solved the puzzle.

"This extraordinary journey has revealed new molecular insights and promising mechanisms for fighting cancer and combating drug-resistant bacteria, and it has challenged the frontiers of chemistry and biology. Now the new biological knowledge and chemical ability we have can be used to develop the next generation of antibiotics and anticancer agents."

It has been predicted that by 2050 an additional 10 million people will succumb to drug-resistant infections each year. The development of new antibiotics which can be used as a last resort when other drugs are ineffective is therefore a crucial area of study for healthcare researchers around the world. This new study represents an important step towards making this end goal a reality.

Kedarcidin's anticancer properties also make it a fascinating subject for scientists exploring new ways of tackling aggressive cancerous tumors. Now it is possible to recreate the substance synthetically, researchers will be able to gain a greater insight into the mechanisms which make it so effective against leukemia and melanoma cells for example.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
EURESTOP network aims to tackle antibiotic resistance crisis